




Network-based analysis of mouse testicular phosphoproteome

Yu Xue


Huazhong University of Science and Technology





Human Proteome Project


- Little known: **2/3** of the 20,300 protein-coding human genes
- ~6000 (30%) genes lack the protein information
- **HPP:**
 - ◆ Mass spectrometry, antibody, and bioinformatics
 - ◆ Quantitative, sequencing, and PTMs
 - ◆ In health and disease
- **Chromosome-Centric Human Proteome Project:**
 - ◆ Complete proteome
 - ◆ Genome annotation
- **2014, CNHPP: encyclopedia**





Phosphoproteomics

- Large-scale identification of “*in vivo*” phosphorylation/PTM sites
- Data integration & resources
 - ◆ dbPTM 3.0: 208,521 PTM sites
 - ◆ SysPTM 2.0: 471,109 PTM sites, 53,235 proteins
- Prediction of regulatory kinases
 - ◆ PKIS: composition of monomer spectrum (CMS)
 - ◆ PSEA: Phosphorylation Set Enrichment Analysis




Li et al., *Database*, 2014, 2014:bau025

Lu et al., *NAR*, 2013, 41:D295-305

Zou et al., *BMC Bioinformatics*, 2013, 14:247


Suo et al., *Sci Rep.*, 2014, 4:4524





What can we learn?

- Poor protein-PTM correlation
- vertebrate-specific functional modules (VFMs) are more conserved than basic functional modules (BFMs)
- Phosphorylation Sites has strong subcellular specificity
- **Non-functional** p-sites: 65%



Cell Reports

Resource

In Vivo SILAC-Based Proteomics Reveals Phosphoproteome Changes during Mouse Skin Carcinogenesis

Wang et al., MBE, 2011, 28:1131-40

Chen et al. Bioinformatics. 2014, pii: btu598


Landry et al., Trends Genet., 2009, 25:193-7





Functional PTM prediction

- **How many PTM events are functional?**
 - ◆ Molecular mechanisms
 - ◆ Biological forecasting
 - ◆ Drug targets
- **A big problem:**
 - ◆ The reproducibility is low
- **A network approach: reverse engineering**
 - ◆ Site-specific kinase-substrate network
 - ◆ NetworKIN & **iGPS**: motif + PPI
 - ◆ Tissue-specific: protein expression data




Bodenmiller et al., Nat Methods, 2007, 4:231-7

Linding et al. (2007) Cell, 129, 1415-1426

Song et al., MCP, 2012, 11: 1070-1083

Wang et al., ISB2013, 129-133







Phosphoproteomics-based network medicine

- Kinases: targets of ~75% of complex diseases
- Hypothesis: more sites, higher activity
 - ◆ **iKING**: integrative KINase Gauge
 - ◆ **KSEA**: Kinase-substrate enrichment analysis

Birds of a feather flock together




More sites, higher activity



Liu, et al., *FEBS J*, 2013, 280:5696-704

Song et al., *MCP*, 2012, 11: 1070-1083

Casado, et al. *Sci Signal*, 2013, 6, rs6





Semen quality

- Decreasing quality of semen in western countries
- Semen quality is poor in China
 - ◆ Associated: region, season & abstinence duration
 - ◆ No effect: Age, smoking, alcohol use & BMI





Table III. Summary of semen parameters

Semen parameters	n	Median	Percentage lower than WHO criteria ^c
Semen volume (ml)	1191	2.3	22.3
Sperm concentration (10 ⁶ /ml)	1191	65	4.8
Sperm count (10 ⁶ per ejaculation)	1191	154	7.1
Rapid progressive motility (A%) ^a	985	19	81.9
Sperm progressive motility [(A + B)%] ^a	985	46	60.7
Total motile spermatozoa [(A + B + C)%] ^a	985	67	NA
Sperm viability (%)	1191	70	61.8
Normal morphology (%) ^b	1131	39	12.4

Carlsen et al., *BMJ*, 1992, 305:609-13

Gao et al., *Hum Reprod.*, 2007, 22:477-84


Li et al., *Hum Reprod.*, 2009, 24:459-69





Spermatogenesis


- **Sperm-generating process**
 - ◆ Mitosis of spermatogonia (精原)
 - ◆ Meiosis of spermatocytes (精母)
 - ◆ Spermiogenesis of spermatids
 - ◆ ~1,000 sperms per heart beat
- **Phosphorylation regulated**
 - ◆ MAPKs, CDC2, POLO-like kinases (PLKs)





Phosphoproteomics


- **Swiss-Webster mice, Nine organs**
 - ◆ brain, brown fat, heart, liver, lung, kidney, pancreas, spleen, & testis
- **Phosphoproteomic identification**
 - ◆ ~36,000 p-sites, 6296 proteins
 - ◆ Different network topologies
- **Limitations**
 - ◆ 3-week-old male
 - ◆ No sperms at all





Our strategy


- **Adult C57BL/6 mice**
 - ◆ 8-week-old male
 - ◆ six testes/replicate
- **Phosphopeptide enrichment**
 - ◆ IMAC: doubly replicated
 - ◆ TiO_2 : triply replicated





Testicular phosphoproteome



- Total: 17,829 p-sites in 3,955 proteins
 - ◆ IMAC: 12,670 sites
 - ◆ TiO₂: 11,309 sites
- The residue distribution is similar





IMAC & TiO₂


- The data overlapping is limited
 - ◆ IMAC: ~48% identified by TiO₂
 - ◆ 8.7% covered in all replicates










Comparison

- **Gygi's: 11,713 p-sites in 3,087 proteins**
 - ◆ ~27% covered by our data set





GO analysis: similar!





Network construction

- **iGPS: 'in vivo' GPS**
 - ◆ <http://igps.biocuckoo.org>
 - ◆ site-specific kinase-substrate relations (ssKSRs)
- **kinase-substrate phosphorylation networks (KSPN)**
 - ◆ 17,065 edges, 402 kinases, 1,066 substrates

iGPS 1.0 - GPS algorithm with the interaction filter

File Tools Help

Phosphorylation

- Protein Kinase
 - Serine/Threonine Kinase
 - AGC
 - AKT
 - DMPK
 - GRK
 - PKA
 - PKB
 - PKC
 - PKG
 - RSK
 - SGK
 - CAMK
 - CMGC
 - STE
 - TKL
 - Atyypical
 - Other
 - Tyrosine Kinase
 - TK

Predicted Site-specific Kinase-substrate Relations

Position	Code	Peptide	Matched ID	Gene Name	Kinase ID	Kinase Name	Interaction
LVEDKPGpSR							
179	S	LVEDRPGSRRRRSYS	ASK644	SFRS4	Q9NYV4	CRK7	String
179	S	LVEDRPGSRRRRSYS	ASK644	SFRS4	P11802	CDK4	String
179	S	LVEDRPGSRRRRSYS	ASK644	SFRS4	Q00537	PCTAIRE2	String
179	S	LVEDRPGSRRRRSYS	ASK644	SFRS4	Q00538	PCTAIRE1	String
179	S	LVEDRPGSRRRRSYS	ASK644	SFRS4	Q00535	CDK5	String
179	S	LVEDRPGSRRRRSYS	ASK644	SFRS4	Q00534	CDK6	String
179	S	LVEDRPGSRRRRSYS	ASK644	SFRS4	Q94921	PFTAIRE1	String
179	S	LVEDRPGSRRRRSYS	ASK644	SFRS4	Q13523	FRF4	String
179	S	LVEDRPGSRRRRSYS	ASK644	SFRS4	Q92330	DYRK2	String
179	S	LVEDRPGSRRRRSYS	ASK644	SFRS4	Q91520	DYRK4	String
179	S	LVEDRPGSRRRRSYS	ASK644	SFRS4	Q94206	HIPK2	String
179	S	LVEDRPGSRRRRSYS	ASK644	SFRS4	Q95702	HIPK1	String
179	S	LVEDRPGSRRRRSYS	ASK644	SFRS4	Q81E63	HIPK4	String
179	S	LVEDRPGSRRRRSYS	ASK644	SFRS4	Q43781	DYRK3	String
179	S	LVEDRPGSRRRRSYS	ASK644	SFRS4	Q13627	DYRK1A	Exp/String
179	S	LVEDRPGSRRRRSYS	ASK644	SFRS4	Q9Y453	DYRK1B	Exp/String
179	S	LVEDRPGSRRRRSYS	ASK644	SFRS4	Q9H422	HIPK3	Exp/String

Enter the data in PhosPep/ELM/FASTA format

```



INCLSpTESTDTPKAPITLPSAREQIMaTLGER
NOKPQVNGAPGpSPTEPADQK
QLVAAYGdSDNEEELVER
AFGAIGYpSQAIVLDR
pSAPPpSPPPGTR
DLDEDELLGNLpSETLK
SFPKIPVpPpSPSWGSCR
KvpSPVK
EGMNPYSYDEYAdpSDEDQHDAYLER
  
```

Options

Organism: H. sapiens | Format: PhosPep | Threshold: Low | Interaction: Exp/String

Console


PhosPep | Network | Clear | Submit





Spermatogenesis-related KSPN

- Spermatogenesis-related proteins
 - ◆ QuickGO: spermatogenesis (GO:0007283)
 - ◆ Spermatogenesis *Online* database
- Sub-KSPN: 106 proteins, 371 edges






Kinases with higher activities




- Background: ~36,000 p-sites in 9 organs
- iKING: top15 kinases with highest activities





Kinase with higher activity


- **MAPKs**
 - ◆ ectoplasmic specialization dynamics
 - ◆ p -value < 0.05: JNK2, ERK2 and p38s
- **CDK2: chromosome pairing in meiosis**
- **CDC2: sperm activity and testicular function**



Li et al., Trends Mol Med., 2009, 15:159-68


Viera et al., J Cell Sci., 2009, 122:2149-59

Shi et al., Toxicol Lett., 2013, 221:91-101







Polo-like kinases (Plks)



0.1



Phosphorylation Phospho-binding





PIK1-PBD interact with Phos-Mis18B





B.

Position	Peptide	Score	CuBit	Type
14	RRRRCATDFPRLPC	6.440	5.208	Phospho-binding
40	RRRRCATDFPRLPC	6.440	5.208	Phospho-binding
221	RRLLSEFDFQRR	6.811	5.208	Phospho-binding



GPS-Polo 1.0

T14, S48, T221





PIk1 co-localizes with Mis18B





Kinetochores





PIK1 phospho-binding regulates Mis18B stability




A.




B.





A potential role in testis?

- PIks: Not annotated in *SpermatogenesisOnline*
- Pik sub-KSPN: 122 proteins, 499 edges
 - Substrates: many spermatogenesis-related proteins
 - Phenotypes: cell morphology related




Phenotype ID	Description	p-value
MP:0003111	Abnormal cell nucleus morphology	2.26E-10
MP:0003077	Abnormal cell cycle	5.71E-08
MP:0004046	Abnormal mitosis	8.76E-08
MP:0000358	Abnormal cell morphology	3.10E-07
MP:0002022	Increased lymphoma incidence	3.97E-07
MP:0002020	Increased tumor incidence	4.03E-07
MP:0010274	Increased organ/body region tumor incidence	5.83E-07
MP:0002019	Abnormal tumor incidence	9.06E-07



Experiments


- **Spermatocyte GC2 cell line**
- **BI2536: PIks inhibitor**
- **Okadaic acid (OA)**
 - ◆ **Phosphatase inhibitor**
 - ◆ **Reverses the phosphorylation changes after inhibition of PIks**
- **DMSO: control**
- **RT-PCR: PIk1-3 existence**






Validation of Plk activation

- pT210: the major p-site and correlates with Plk1 activity
- Testes: 1, 2, 3, 4, 8 weeks
- Control: 8 tissue mixtures; 3 and 8 weeks
- Plk1 activity is significantly higher



Jang et al., *J Biol Chem.*, 2002, 277:44115-20

Kelm et al., *J Biol Chem.*, 2002, 277:25247-56







Plk inhibition: G2/M arrest

- After 6h
 - ◆ G1 cells: decreased
 - ◆ S cells: unchanged
 - ◆ G2/M cells: increased
- BI2536: induces arrest in the G2/M phase and inhibits cell proliferation

2h culture



6h culture






Discussion

- **The differential activities of kinases can be readily and robustly predicted from poorly reproducible data**
- **Plk1: colon and lung cancers**
- **Plk inhibitors: potential anti-cancer drugs**
 - ◆ **BI2536: Phase I and II**
 - ◆ **BI6727/Volasertib: granted by the FDA in AML (with cytarabine), in older patients**
 - ◆ **GSK461364A: Phase I**

VOLASERTIB*

*This compound is an investigational agent.
Its safety and efficacy have not been established.

VOLASERTIB*, AN INVESTIGATIONAL POLO-LIKE KINASE (PLK) INHIBITOR





Perspectives

- **Biological forecasting: network-based prediction**
- **Network targets in Liver cancers and neurodegenerative diseases**
- **Key regulators in Autophagy**
- **Can we learn more things from the phosphoproteomic data?**





Acknowledgements

- **Zexian Liu (HUST)**
- **Jian Ren (SYSU)**
- **Jiahao Sha & Xuejiang Guo (NJMU)**
- **Luonan Chen (Sysbio)**
- **Hanfa Zou & Mingliang Ye (DICP)**
- **Ping Xu (BPRC)**
- **Min Li (HKBU)**
- **Longping Wen (USTC)**
- **Members of the CUCKOO Workgroup**





Thanks!



Any questions?

